Vaccines Using Macrophage Suppression

Abstract

Researchers at the University of California, Davis have developed a technology that introduces vaccines that express macrophage-suppressing molecules to significantly enhance inflammatory T-cell functions for improved immune responses.

Full Description

The vaccines utilize macrophage-suppressing molecules and novel IL-10 variants and fusion proteins to promote the development of a substantial quantity of antigen- or cancer-specific T cells. These T cells are capable of secreting inflammatory cytokines and responding to MHC class-Ib-restricted "supertopes," leading to improved vaccine efficacy with reduced toxicity.

Applications

• Development of effective vaccines for infectious diseases and cancer. 
• Customizable platforms for vaccine development across various diseases with enhanced T-cell mediated immunity. 
• Therapeutic interventions for diseases requiring targeted T-cell responses without the adverse effects of generalized immune activation.

Features/Benefits

• Reduces vaccine-associated toxicity while enhancing immune response. 
• Generates a larger quantity of antigen- or cancer-specific T cells secreting inflammatory cytokines. 
• Facilitates the development of T cells capable of IFN-gamma secretion, targeting MHC class-Ib molecules such as HLA-E. 
• Adaptable to multiple vaccine vector platforms, increasing versatility. 
• Reduces non-specific inflammatory effects and toxicity commonly associated with T-cell activation in vaccines. 
• Overcomes the limitations of current methods that fail to reliably expand T cells responding to "supertopes" and restricted by MHC class-Ib molecules. 
• Addresses the challenge of off-target effects and complexity in cytomegalovirus-vectored vaccines.

Patent Status

Patent Pending